NMI TT

We are delighted to see that our DigiWest® data contributed to this exciting Nature Communications article

We are proud to announce the availability of DigiWest® and RPPA multiplex protein profiling from FFPE samples

International multisite study of human induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment

We are pleased to announce the availability of pathway panels for our DigiWest® multiplex immunoassay-based protein profiling services

We are excited to announce our most recent offering: modified MagPlex® microspheres for Luminex® assays

NMI TT Pharmaservices and Charité received a grant for protein profiling in individualization of tumor therapy

We are very excited that HESI changed our status from non-core to core site for the actual running CiPA myocyte study

NMI and its CRO NMI TT Pharmaservices announce the publication of their proprietary DigiWest® protein profiling method in Nature Communications

Come to Reutlingen, and hear about the latest advances in Reverse Phase Protein Arrays (RPPAs) and their application for biomarker research

Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for treatment of Fragile X Syndrome (FXS)

Cav1.2 ion channels are expressed in heart, smooth muscle and neurons, and therefore are therapeutic targets in cardiac arrhythmia and hypertension

News